OA11583A - Use of glucose uptake enhancer for reducing post-ischemic injury of the heart. - Google Patents

Use of glucose uptake enhancer for reducing post-ischemic injury of the heart. Download PDF

Info

Publication number: OA11583A
Authority: OA; OAPI
Prior art keywords: compound; heart; glucose uptake; uptake enhancer; pharmaceutically acceptable
Prior art date: 1998-07-21

Application number

OA1200100021A

Other languages

English (en)

Inventor

Antoine Michel Alain Bril

Robin Edwin Buckingham

Nassirah Khandoudi

Original Assignee

Smithkline Beecham Plc

Smithkline Beecham Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-21

Filing date

1999-07-21

Publication date

2004-07-01

1998-07-21 Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en

1998-07-21 Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en

1999-07-21 Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc

2004-07-01 Publication of OA11583A publication Critical patent/OA11583A/en

Links

239000003623 enhancer Substances 0.000 title claims abstract description 31
230000004190 glucose uptake Effects 0.000 title claims abstract description 30
208000037906 ischaemic injury Diseases 0.000 title claims abstract description 11
238000000034 method Methods 0.000 claims abstract description 26
229940123464 Thiazolidinedione Drugs 0.000 claims abstract description 22
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims abstract description 15
238000011084 recovery Methods 0.000 claims abstract description 15
208000031225 myocardial ischemia Diseases 0.000 claims abstract description 7
231100000252 nontoxic Toxicity 0.000 claims abstract description 5
230000003000 nontoxic effect Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 54
239000000203 mixture Substances 0.000 claims description 22
239000008194 pharmaceutical composition Substances 0.000 claims description 8
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 8
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 8
229960001641 troglitazone Drugs 0.000 claims description 6
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 6
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 3
229950009226 ciglitazone Drugs 0.000 claims description 2
229960005095 pioglitazone Drugs 0.000 claims description 2
LMWZLUIVVPBIQZ-UHFFFAOYSA-N 1-oxothiolan-2-one Chemical group O=C1CCCS1=O LMWZLUIVVPBIQZ-UHFFFAOYSA-N 0.000 claims 1
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 1
229950002375 englitazone Drugs 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 description 19
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
241000700159 Rattus Species 0.000 description 14
230000001154 acute effect Effects 0.000 description 14
208000028867 ischemia Diseases 0.000 description 11
150000001467 thiazolidinediones Chemical class 0.000 description 11
230000000747 cardiac effect Effects 0.000 description 10
102000004877 Insulin Human genes 0.000 description 9
108090001061 Insulin Proteins 0.000 description 9
229940125396 insulin Drugs 0.000 description 9
208000010125 myocardial infarction Diseases 0.000 description 9
230000010412 perfusion Effects 0.000 description 9
231100000489 sensitizer Toxicity 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
241000700157 Rattus norvegicus Species 0.000 description 8
230000003293 cardioprotective effect Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000008103 glucose Substances 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
238000002474 experimental method Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
230000002861 ventricular Effects 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000002058 anti-hyperglycaemic effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000004217 heart function Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
241000220479 Acacia Species 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010023197 Streptokinase Proteins 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229940045200 cardioprotective agent Drugs 0.000 description 2
239000012659 cardioprotective agent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000009760 functional impairment Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
-1 methylcyclohexyl Chemical group 0.000 description 2
238000002156 mixing Methods 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
229960005202 streptokinase Drugs 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960000103 thrombolytic agent Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108030001204 Myosin ATPases Proteins 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000010016 myocardial function Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
230000036316 preload Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960000340 thiopental sodium Drugs 0.000 description 1
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000013293 zucker diabetic fatty rat Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

OA1200100021A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart. OA11583A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9815871.0A GB9815871D0 (en)	1998-07-21	1998-07-21	Novel compound
GBGB9815872.8A GB9815872D0 (en)	1998-07-21	1998-07-21	Novel method

Publications (1)

Publication Number	Publication Date
OA11583A true OA11583A (en)	2004-07-01

Family

ID=26314086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100021A OA11583A (en)	1998-07-21	1999-07-21	Use of glucose uptake enhancer for reducing post-ischemic injury of the heart.

Country Status (35)

Country	Link
EP (2)	EP1098638B1 (fr)
JP (1)	JP2002521325A (fr)
KR (1)	KR20010079550A (fr)
CN (1)	CN1167416C (fr)
AP (1)	AP1416A (fr)
AR (1)	AR020614A1 (fr)
AT (1)	ATE318588T1 (fr)
AU (1)	AU5053599A (fr)
BG (1)	BG105251A (fr)
BR (1)	BR9912144A (fr)
CA (1)	CA2338216A1 (fr)
CO (1)	CO5060465A1 (fr)
CY (1)	CY1106078T1 (fr)
CZ (1)	CZ2001250A3 (fr)
DE (1)	DE69930125T2 (fr)
DK (1)	DK1098638T3 (fr)
DZ (1)	DZ2854A1 (fr)
EA (1)	EA004772B1 (fr)
ES (1)	ES2259839T3 (fr)
GC (1)	GC0000173A (fr)
HU (1)	HUP0103870A3 (fr)
ID (1)	ID27850A (fr)
IL (1)	IL140741A0 (fr)
MA (1)	MA26662A1 (fr)
NO (1)	NO20010293L (fr)
NZ (1)	NZ509175A (fr)
OA (1)	OA11583A (fr)
PE (1)	PE20000881A1 (fr)
PL (1)	PL345663A1 (fr)
PT (1)	PT1098638E (fr)
SI (1)	SI1098638T1 (fr)
SK (1)	SK1022001A3 (fr)
TR (1)	TR200100208T2 (fr)
TW (2)	TWI239836B (fr)
WO (1)	WO2000004889A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6417212B1 (en)	1999-08-27	2002-07-09	Eli Lilly & Company	Modulators of peroxisome proliferator activated receptors
BR0017254A (pt) *	2000-06-16	2004-01-06	Smithkline Beecham Plc	Tratamento e prevenção de condições associadas à resistência cardìaca à insulina
JP4425628B2 (ja)	2001-07-23	2010-03-03	ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド	細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0842925A1 (fr) *	1987-09-04	1998-05-20	Beecham Group Plc	Thiazolidinédiones substituées
JPH05202042A (ja) *	1992-01-24	1993-08-10	Sankyo Co Ltd	糖尿病性合併症治療剤
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
GB9611947D0 (en) *	1996-06-07	1996-08-07	Glaxo Group Ltd	Medicaments
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
ID21778A (id) *	1996-09-12	1999-07-22	Sankyo Co	Zat peningkat aktifitas glutation reduktase yang mengandung troglitazon
WO1999025346A1 (fr) *	1997-11-19	1999-05-27	Takeda Chemical Industries, Ltd.	Nouvel inhibiteur d'apoptose
AU2781899A (en) *	1998-02-24	1999-09-15	Trustees Of The University Of Pennsylvania, The	Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (fr) *	1998-05-19	1999-11-25	Regents Of The University Of California	Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
US5968960A (en) *	1999-01-14	1999-10-19	The Regents Of The University Of California	Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

1999
- 1999-07-19 MA MA25690A patent/MA26662A1/fr unknown
- 1999-07-20 PE PE1999000726A patent/PE20000881A1/es not_active Application Discontinuation
- 1999-07-21 DE DE69930125T patent/DE69930125T2/de not_active Expired - Fee Related
- 1999-07-21 JP JP2000560882A patent/JP2002521325A/ja not_active Withdrawn
- 1999-07-21 EP EP99934911A patent/EP1098638B1/fr not_active Expired - Lifetime
- 1999-07-21 GC GCP1999211 patent/GC0000173A/en active
- 1999-07-21 SI SI9930889T patent/SI1098638T1/sl unknown
- 1999-07-21 PL PL99345663A patent/PL345663A1/xx not_active Application Discontinuation
- 1999-07-21 TW TW088112356A patent/TWI239836B/zh not_active IP Right Cessation
- 1999-07-21 BR BR9912144-1A patent/BR9912144A/pt not_active IP Right Cessation
- 1999-07-21 CZ CZ2001250A patent/CZ2001250A3/cs unknown
- 1999-07-21 KR KR1020017000924A patent/KR20010079550A/ko not_active Ceased
- 1999-07-21 DK DK99934911T patent/DK1098638T3/da active
- 1999-07-21 PT PT99934911T patent/PT1098638E/pt unknown
- 1999-07-21 DZ DZ990154A patent/DZ2854A1/fr active
- 1999-07-21 OA OA1200100021A patent/OA11583A/en unknown
- 1999-07-21 HU HU0103870A patent/HUP0103870A3/hu unknown
- 1999-07-21 ID IDW20010151A patent/ID27850A/id unknown
- 1999-07-21 TR TR2001/00208T patent/TR200100208T2/xx unknown
- 1999-07-21 NZ NZ509175A patent/NZ509175A/en unknown
- 1999-07-21 CN CNB998089826A patent/CN1167416C/zh not_active Expired - Fee Related
- 1999-07-21 CO CO99045729A patent/CO5060465A1/es unknown
- 1999-07-21 WO PCT/GB1999/002358 patent/WO2000004889A1/fr not_active Ceased
- 1999-07-21 IL IL14074199A patent/IL140741A0/xx unknown
- 1999-07-21 AR ARP990103577A patent/AR020614A1/es not_active Application Discontinuation
- 1999-07-21 TW TW092103470A patent/TW200307532A/zh unknown
- 1999-07-21 AT AT99934911T patent/ATE318588T1/de not_active IP Right Cessation
- 1999-07-21 AU AU50535/99A patent/AU5053599A/en not_active Abandoned
- 1999-07-21 EP EP04077992A patent/EP1523980A3/fr not_active Withdrawn
- 1999-07-21 SK SK102-2001A patent/SK1022001A3/sk unknown
- 1999-07-21 ES ES99934911T patent/ES2259839T3/es not_active Expired - Lifetime
- 1999-07-21 CA CA002338216A patent/CA2338216A1/fr not_active Abandoned
- 1999-07-21 AP APAP/P/2001/002033A patent/AP1416A/en active
- 1999-07-21 EA EA200100164A patent/EA004772B1/ru not_active IP Right Cessation
2001
- 2001-01-18 NO NO20010293A patent/NO20010293L/no unknown
- 2001-02-14 BG BG105251A patent/BG105251A/xx unknown
2006
- 2006-05-12 CY CY20061100616T patent/CY1106078T1/el unknown

Also Published As

Publication number	Publication date
CZ2001250A3 (cs)	2002-03-13
NZ509175A (en)	2003-10-31
NO20010293D0 (no)	2001-01-18
KR20010079550A (ko)	2001-08-22
DE69930125T2 (de)	2006-10-05
CN1310619A (zh)	2001-08-29
BG105251A (en)	2001-10-31
ID27850A (id)	2001-04-26
TW200307532A (en)	2003-12-16
TR200100208T2 (tr)	2001-05-21
EA004772B1 (ru)	2004-08-26
CY1106078T1 (el)	2011-06-08
DZ2854A1 (fr)	2003-12-01
SI1098638T1 (sl)	2006-06-30
ES2259839T3 (es)	2006-10-16
EP1523980A3 (fr)	2009-03-18
HUP0103870A3 (en)	2003-06-30
EP1098638A1 (fr)	2001-05-16
AP2001002033A0 (en)	2001-03-31
AP1416A (en)	2005-06-13
BR9912144A (pt)	2001-04-03
PT1098638E (pt)	2006-07-31
ATE318588T1 (de)	2006-03-15
CO5060465A1 (es)	2001-07-30
CN1167416C (zh)	2004-09-22
EA200100164A1 (ru)	2001-08-27
NO20010293L (no)	2001-03-07
CA2338216A1 (fr)	2000-02-03
DE69930125D1 (de)	2006-04-27
PE20000881A1 (es)	2000-10-07
TWI239836B (en)	2005-09-21
SK1022001A3 (en)	2001-08-06
PL345663A1 (en)	2002-01-02
HUP0103870A2 (hu)	2002-05-29
EP1523980A2 (fr)	2005-04-20
EP1098638B1 (fr)	2006-03-01
GC0000173A (en)	2006-03-29
MA26662A1 (fr)	2004-12-20
AU5053599A (en)	2000-02-14
AR020614A1 (es)	2002-05-22
DK1098638T3 (da)	2006-06-19
IL140741A0 (en)	2002-02-10
WO2000004889A1 (fr)	2000-02-03
JP2002521325A (ja)	2002-07-16

Publication	Publication Date	Title
US6699889B2 (en)	2004-03-02	Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
OA11583A (en)	2004-07-01	Use of glucose uptake enhancer for reducing post-ischemic injury of the heart.
EP1098639B1 (fr)	2005-02-09	Utilisation de l'activateur d'assimilation du glucose rosiglitazone pour reduire l'apoptose due a l'ischemie des cellules pancreatiques beta, des cellules endotheliales et des cellules neuronales
US20020099082A1 (en)	2002-07-25	Use of glucose uptake enhancer for reducing apoptosis
AU2768302A (en)	2002-05-16	Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
ZA200100438B (en)	2002-10-04	Use of glucose uptake enhancer for reducing apoptosis.
AU2768402A (en)	2002-05-16	Use of glucose uptake enhancer for reducing apoptosis
HK1037865B (en)	2005-11-25	Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells
US20010031776A1 (en)	2001-10-18	Use of thiazolidinediones for the treatment of hyperglycaemia
OA11519A (en)	2004-02-09	Use of thiazolidinediones for the treatment of hyperglycaemia.
MXPA00003634A (en)	2001-05-07	Use of thiazolidinediones for the treatment of hyperglycaemia
CA2306086A1 (fr)	1999-04-22	Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie
AU4586902A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia